Slingshot members are tracking this event:
Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jun 13, 2016
- Comparing Aimmune's (AIMT) Peanut Allergy Medication AR101 to DBV Technology's (DBVT) Viaskin Peanut As They Race for FDA Approval AIMT, DBVT Executed On: Jun 23, 2016 at 11:00 AM EDT
Related Keywords Ar101, Peanut Allergy